These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Brentuximab vedotin in CD30 Stranzenbach R; Dippel E; Schlaak M; Stadler R Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284 [TBL] [Abstract][Full Text] [Related]
5. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744 [TBL] [Abstract][Full Text] [Related]
7. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350 [TBL] [Abstract][Full Text] [Related]
9. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247 [TBL] [Abstract][Full Text] [Related]
10. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441 [TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Shea L; Mehta-Shah N Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790 [TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137 [TBL] [Abstract][Full Text] [Related]
14. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Welborn M; Duvic M Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444 [TBL] [Abstract][Full Text] [Related]
15. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003 [TBL] [Abstract][Full Text] [Related]
16. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas. Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021 [TBL] [Abstract][Full Text] [Related]
17. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Karube K; Kakimoto Y; Tonozuka Y; Ohshima K Expert Rev Hematol; 2021 Aug; 14(8):777-787. PubMed ID: 34263699 [TBL] [Abstract][Full Text] [Related]
18. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Oak E; Bartlett NL Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791 [No Abstract] [Full Text] [Related]